
Science Unpacks the Healing Potential of Your Own Blood
Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy.
If you were to shrink yourself down to smaller than a sugar crystal and travel into someone's veins like Ms. Frizzle and her Magic School Bus, you'd see that blood isn't the free-flowing river depicted in your childhood storybooks. Rather, you'd find an intricate ecosystem suspended in plasma: disc-like red blood cells carrying oxygen through the body; bumpy white blood cells warding off infection; and tiny platelets with octopus-like tentacles directing healing. Rich in growth factors, platelets are often considered the gold standard for regenerative medicine.
In platelet-rich plasma treatments, or PRP, doctors spin a patient's blood in a centrifuge to single out the platelets and the plasma, creating a healing elixir that can be added back into a patient's body. PRP has long been used for promoting hair growth, improving skin, and healing injuries. The next generation of PRP is called PRF, which may offer more sustained healing and collagen production over time. 'PRF stands for 'platelet-rich fibrin,'' says Lara Devgan, MD, a plastic surgeon in New York. 'It harnesses the body's own growth factors to stimulate collagen, improve skin texture, and restore volume without fillers.' For patients, PRP and PRF extractions for cosmetic or therapeutic use just involve a simple blood draw. They're much less expensive than a hair transplant, and may produce a more natural result than other skin injectables.
If PRP is an iPhone, PRF is the Pro version, leading to potentially longer-lasting results. This may be because it contains fibrin, which aids in blood clotting; a 2011 study in Annals of Maxillofacial Surgery found that PRF may speed healing, since it helps the body form new blood vessels. Thanks to fibrin, PRF unleashes growth factors more slowly than PRP. Because it's mixed at a higher speed, PRP expels a flood of growth factors—which act like messengers between and within cells, pinging information back and forth to ensure everything is in tip-top shape—all at once. In contrast, PRF releases these healing agents over 7 to 10 days, which may enhance tissue regeneration, says Gabriel Chiu, DO, a plastic surgeon in Beverly Hills.
PRF was developed to bypass some of PRP's limits. PRP is often mixed with anticoagulants, which in some cases may cause allergic reactions and hinder the platelets' regenerative power, according to a 2020 study published in Frontiers in Bioengineering and Biotechnology. PRF, which is spun more slowly, is made without anticoagulants and so 'has the least risk for someone [with] sensitivity issues,' Chiu explains.
Still, both Devgan and Chiu agree that in some cases, PRP remains the better option. It's an easier-to-disperse fluid, so it's better for larger treatment areas. PRP is best for hair loss, since it can be micro-needled in, whereas PRF's thicker solution must be injected. But when it comes to targeted treatment for lines, wrinkles, and hollow under-eyes, PRF may be the more potent remedy since it softens the face, according to Chiu. He also uses PRF as a 'glue' when he does a facelift. It helps tissues adhere to each other, and may boost healing.
Though PRF can appear to 'fill' under-eye hollows by helping skin quality and firmness, it won't add volume, like filler. A PRF treatment is akin to upping the thread count of your sheets, Devgan says. Skin enhanced by PRF versus normal skin is like the difference between sheets made from 350-thread-count Egyptian cotton and run-of-the mill 200-thread-count sheets. 'It's not like making a bedsheet into a comforter,' she says. But who doesn't want an amazing set of sheets?
A version of this story appears in the Summer 2025 issue of ELLE.
GET THE LATEST ISSUE OF ELLE
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) ('Helius' or the 'Company'), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. 'The recent reimbursement approvals from two major commercial healthcare payers, with a third underway, mark significant milestones for Helius and the MS community,' said Dane Andreeff, Helius' President and Chief Executive Officer. 'We are actively pursuing broader in-network coverage for PoNS at list price from major commercial payers, while continuing to negotiate reimbursement on a case-by-case basis. We expect to continue our efforts in expanding patient access and ensuring consistent reimbursement as we work to align commercial payments with the rates currently offered by the VA/DoD at $26,228. At the same time, we remain firmly committed to supporting individuals with MS who rely on Medicare for PoNS treatment and believe this, along with other 3rd party payer reimbursement decisions will benefit our continued efforts to secure fair and adequate reimbursement by CMS for the PoNS system.' The out-of-network price, which typically is 30 to 40% below in-network contracted payment rates of $18,350, was negotiated and accepted by Aetna Healthcare to fulfill the prescription of the PoNS Device for an individual with multiple sclerosis. Depending on the individual's deductible and out-of-pocket costs, this claim may not result in an immediate PoNS Device sale. About the PoNS Device and PoNS Therapy The Portable Neuromodulation Stimulator ('PoNS') is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it's used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ('mmTBI') and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short-term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS® or Helius Medical Technologies, visit Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, statements regarding commercial reimbursement of the PoNS Device and the uses and effectiveness of PoNS and PoNS Therapy. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties associated with the Company's capital requirements to achieve its business objectives, availability of funds, the Company's ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company's ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company's ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip TaylorGilmartin Groupinvestorrelations@ in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
19 hours ago
- Yahoo
'Gambling addiction cost my sick mum thousands'
The daughter of a woman who became addicted to slot machines and lost thousands while undergoing cancer treatment is calling on the government to introduce tougher controls. Jackie Olden said her late mother Wendy Hughes got hooked after working at a bookmakers where she was asked to play the machines on a free demonstration mode to help drum up customer interest. She said it prompted Ms Hughes, who died from cancer in 2024 at the age of 64, to begin playing slots in her own time before spiralling into debt. Ms Olden said: "My mum was never someone who would have gambled before this, she was absolutely dedicated to her family." She said her mother, a widow, had worked hard to make ends meet while raising her three children in Stockport, Greater Manchester. "She had her own house and some money saved but all of that just went and it went really, really, really quickly," Ms Olden said. Ms Hughes's children intervened in an attempt to get her excluded from gambling outlets but she relapsed years later after discovering 24-hour adult gaming centres. Ms Olden said: "When I found out, I was absolutely flabbergasted to hear that there are 24-hour slot machine places on almost every high street in the UK. "In Stockport, where I live, there are three of them." Ms Hughes continued gambling after being diagnosed with cancer in April 2023 and became progressively more unwell. In November of the same year, she lost almost £2,000 pounds in two sessions at the Merkur slots venue in Stockport. The German company was fined £95,450 earlier this year by the Gambling Commission following a complaint by Ms Hughes, which found the operator failed "to follow rules aimed at keeping consumers safe from harm". In a bid to protect others, Ms Olden earlier delivered a petition with more than 40,000 signatures to Downing Street, calling on the government to give local government stronger powers to refuse licences for gambling venues where concerns are raised. She said: "I'm not an anti-gambling purist or someone who wants to tell people what to do, but these places are so dangerous. "The products in there are known to be the most harmful, the most addictive and I just think we need to regulate them way more tightly." Merkur said the the failure was "due to premises staff not implementing our policies and procedures effectively". They continued: "Customer welfare is our priority and we have conducted a thorough internal review. "As a result, we have strengthened training for our 1,840 venue-based staff as well as enhancing reporting procedures to ensure our high standards are upheld." Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230. Slot machines to go cashless as debit cards allowed
Yahoo
a day ago
- Yahoo
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience ACTON, Mass., June 10, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom's latest diabetes management technology, all conveniently controlled from an iPhone. "This integration represents a major milestone in our commitment to providing innovative solutions for diabetes management," said Eric Benjamin, Insulet Executive Vice President, Chief Product and Customer Experience Officer. "With the addition of the Dexcom G7 sensor to the Omnipod 5 App for iPhone, our U.S. customers have more choice with fewer devices to keep track of, making it easier than ever to manage their diabetes." Omnipod 5 proactively adjusts insulin delivery every five minutes, autocorrects for high glucose, and helps protect against lows*, day and night—even while you sleep. The Omnipod 5 App for iPhone, available in the U.S., offers full control of Omnipod 5 including the ability to bolus, change a Pod, adjust settings, access valuable insights, and more. "The Omnipod 5 App for iPhone means less stress with better control! Plus, I feel like I lost a few pounds, since I don't have to carry around a Controller anymore," joked Garrett Vogel, a nationally syndicated radio personality who has lived with type 1 diabetes for 30 years and has been using Omnipod 5 since 2023. Garrett was previously using Omnipod 5 with Dexcom G7 and the Controller. "I thought bolusing with the Controller was easy, but the Omnipod 5 App on my iPhone makes it even easier. I love it." The Omnipod 5 App with Dexcom G7 and Dexcom G6 compatibility is now available for download on the Apple App Store. Insulet remains dedicated to advancing diabetes technology and improving the lives of people with diabetes. For more information, please visit About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: and *Brown S. et al. Diabetes Care. 2021;44:1630-1640. Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Pasquel FJ et al. JAMA Network Open. 2024;8(2): e2459348. Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people with type 2 diabetes aged 18-75 years. Time above range and below range results measured by CGM. ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners. View source version on Contacts Investor Relations: June LazaroffSenior Director, Investor Relations(978) 600-7717jlazaroff@ Media: Angela Geryak WiczekSenior Director, Corporate Communications(978) 932-0611awiczek@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data